Jun 14, 2020
Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial
Jan 24, 2020
HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future
Jun 17, 2019
FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years
May 22, 2019
Novo Nordisk to present data on oral semaglutide at the 79th Annual American Diabetes Association Scientific Sessions
Apr 28, 2019
Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes
Apr 08, 2019
Novo Nordisk UAE Awarded the Best Place To Work in UAE for 2019
Mar 20, 2019
Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes
Mar 04, 2019
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
Aug 17, 2018
Ziylo Acquired by Novo Nordisk in Deal That Could Exceed US$800m
Jun 18, 2018
Novo Nordisk to present 39 abstracts at the 78th Annual American Diabetes Association Scientific Sessions
May 23, 2018
San Diego-based Epigen Biosciences enters a collaboration to license its LPA1 Receptor small molecule program to Novo Nordisk A/S for up to USD 200 Million
May 16, 2018
BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions
Mar 14, 2018
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Amarin, Apricus Biosciences, United Therapeutics, and Novo Nordisk
Sep 29, 2017
Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin
Aug 15, 2017
Metacrine Announces Collaboration on Development of FGF1 Variants for Glucose Lowering and Improving Insulin Sensitivity
May 31, 2017
FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia